NEKTAR THERAPEUTICS (NKTR)       2.5814  -0.03 (-1.1%)

2.5814  -0.03 (-1.1%)

US6402681083 - Common Stock


Fundamental Rating

2

Taking everything into account, NKTR scores 2 out of 10 in our fundamental rating. NKTR was compared to 258 industry peers in the Pharmaceuticals industry. The financial health of NKTR is medium. Also its profitability is quite bad. While showing a medium growth rate, NKTR is valued expensive at the moment.

Note: NKTR has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

The Piotroski-F score of NKTR is 5.00. This is a neutral score and indicates average health and profitability for NKTR.

VS Industry

Valuation

Valuation Rating

1

When comparing the current price to the book value of NKTR, we can conclude it is valued correctly. It is trading at 1.18 times its book value.
When comparing the price book ratio of NKTR to the average industry price book ratio of 1.48, NKTR is valued in line with its industry peers.

The Price/Earnings Ratio is negative for NKTR. In the last year negative earnings were reported.
Also next year NKTR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Price/Book (1.18) VS Industry: 57% outperformed.

540.62
0.13

Growth

Growth Rating

4

Based on estimates for the next 5 years, NKTR will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.09% on average per year.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
The Earnings Per Share has been growing slightly by 9.96% over the past year.

The Revenue has decreased by -5.29% in the past year.
The Revenue has been decreasing by -9.23% on average over the past 5 years.
The Revenue is expected to grow by 9.46% on average over the next 5 years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 9.96% 23.89% 29.33% 18.5% 13.09%
Revenue-9.23% -55.96% -5.29% -10.78% -5.22% -1.33% 9.46%

Health

Health Rating

4

NKTR has a Current Ratio of 7.14. This indicates that NKTR is financially healthy and has no problem in meeting its short term obligations.
The Current Ratio of NKTR is much better than the industry average of 3.52.
NKTR has a Quick Ratio of 6.91. This indicates that NKTR is financially healthy and has no problem in meeting its short term obligations.
NKTR is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 2.89.

The Debt to Equity ratio of NKTR is in line with the industry averages.
NKTR has a Piotroski-F score of 5.00. This indicates an average health and profitability for NKTR.
NKTR has an Altman-Z score of -5.24. This is a bad value and indicates that NKTR is not financially healthy and even has some risk of bankruptcy.
When comparing the Altman-Z score of NKTR to the average industry Altman-Z score of -0.61, NKTR is less financially healthy than its industry peers.
VS Industry

Debt/Equity (0) VS Industry: 53% outperformed.

59.36
0.00

Quick Ratio (6.91) VS Industry: 71% outperformed.

-2.73
76.82

Current Ratio (7.14) VS Industry: 72% outperformed.

0.10
76.82

Altman-Z (-5.24) VS Industry: 24% outperformed.

-229.49
88.63

Dividend

Dividend Rating

0

No dividends for NKTR!.

NEKTAR THERAPEUTICS2.5814

NASDAQ:NKTR (1/30/2023, 10:59:38 AM)-0.03 (-1.1%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Pharmaceuticals
Earnings (Last) 11-03 2022-11-03/amc Earnings (Next) 02-27 2023-02-27
Inst Owners 93.69% Inst Owner Change -0.01%
Ins Owners 1.77% Ins Owner Change 22.24%
Market Cap 485.18M Analysts 49.33
Price Target 4.5 (74.32%)

Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Surprises & Revisions
EPS beat(2) 2 Avg EPS beat(2) 21.69%
Min EPS beat(2) 10.99% Max EPS beat(2) 32.39%
EPS beat(4) 4 Avg EPS beat(4) 19.19%
Min EPS beat(4) 4.31% Max EPS beat(4) 32.39%
Revenue beat(2) 1 Avg Revenue beat(2) -2.09%
Min Revenue beat(2) -6.63% Max Revenue beat(2) 2.45%
Revenue beat(4) 1 Avg Revenue beat(4) -1.89%
Min Revenue beat(4) -6.63% Max Revenue beat(4) 2.45%
PT rev (1m) 0% EPS NQ rev (1m) 0%
EPS NY rev (1m) 0% Revenue NQ rev (1m) 0%
Revenue NY rev (1m) 0%

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.11
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB 1.45
EV/EBITDA N/A
EPS(TTM) -2.44 EY N/A
EPS(NY) -0.93 Fwd EY N/A
FCF(TTM) -2.18 FCFY N/A
OCF(TTM) -2.12 OCFY N/A
SpS 0.51 BVpS 2.19
TBVpS 1.79 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM 77.31%
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y -8.29% GM growth 5Y -1.56%
F-Score 5 Asset Turnover 0.12

Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.26%
Profit Quality N/A
Current Ratio 7.14
Quick Ratio 6.91
Altman-Z -5.24
F-Score 5 WACC 8.48%
ROIC/WACC N/A Cap/Depr(3y) 118.87%
Cap/Depr(5y) 110.57% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 9.96% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 55.71%
EPS Next Y 23.89% EPS Next 2Y 29.33%
EPS Next 3Y 18.5% EPS Next 5Y 13.09%
Revenue growth 1Y -5.29% Revenue growth 3Y -55.96%
Revenue growth 5Y -9.23% Revenue growth Q2Q -5.2%
Revenue Next Year -10.78% Revenue Next 2Y -5.22%
Revenue Next 3Y -1.33% Revenue Next 5Y 9.46%
EBIT growth 1Y 29.66% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year 15.48%
EBIT Next 3Y 15.51% EBIT Next 5Y N/A
FCF growth 1Y -17.13% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -17.05%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA